Catalyst (CPRX) Files Rule 144 to Sell 20K Shares via Fidelity

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Full Rule 144 disclosure provided, including broker, share count, and aggregate market value
• Securities originated from option exercise (options granted 12/19/2018) with payment in cash
• No sales in past three months reported for the selling person, reducing aggregation complexity
• Transaction size is small relative to total outstanding shares (20,000 vs. 122,391,010)

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice disclosing an intended sale of 20,000 shares acquired by option exercise; immaterial to outstanding share count.

This filing documents a planned sale under Rule 144 of 20,000 common shares valued at approximately $401,514.10. The shares were acquired by exercise of options granted in 2018 and paid for in cash on the acquisition date. Against the issuer's reported outstanding share base of 122,391,010, this planned sale represents a de minimis percentage, suggesting limited direct market impact. The filer also reports no sales in the prior three months and makes the standard attestation regarding undisclosed material information.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure that meets Rule 144 reporting requirements; no governance red flags disclosed.

The form provides required disclosure about the origin of the securities (options granted 12/19/2018) and the mechanics of the proposed sale through a named broker. There is no indication in the document of unusual settlement terms, aggregation with other sellers, or recent insider sales. The representation about lack of undisclosed material information is standard. Based solely on the notice, there are no governance concerns evident from this transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	20000	401514.10	122391010	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/03/2025	Options Granted 12/19/2018	Issuer			20000	09/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by CPRX disclose?

The form discloses a proposed Rule 144 sale of 20,000 common shares through Fidelity with an aggregate market value of $401,514.10 to be traded on NASDAQ.

How were the 20,000 CPRX shares acquired?

The shares were acquired on 09/03/2025 by exercise of options originally granted on 12/19/2018, with payment made in cash.

What is the issuer's reported number of shares outstanding?

The filing lists 122,391,010 shares outstanding.

Does the filing report any sales by the same person in the past three months?

No; the form states "Nothing to Report" for securities sold during the past three months by the selling person.

Through which broker will the CPRX shares be sold?

The broker named in the filing is Fidelity Brokerage Services LLC.